Prageeth R. Wijewardhane

Prageeth R. Wijewardhane

Auto-generated profile, based on publicly available information

Prageeth R. Wijewardhane

Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 47907, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Nature
Verified
Journal Article
Closed access
PDF file
KGKevin A. Guttenplan
Kevin A. Guttenplan
MWMaya K. Weigel
Maya K. Weigel
PPPriya Prakash
Priya Prakash
PWPrageeth R. Wijewardhane
Prageeth R. Wijewardhane
PHPhilip Hasel
Philip Hasel
BBBen A. Barres
Ben A. Barres

21 February 2024 in ACS Measurement Science Au
Verified
Journal Article
Open access
ABArmen G. Beck
Armen G. Beck
MMMatthew Muhoberac
Matthew Muhoberac
CRCaitlin E. Randolph
Caitlin E. Randolph
CBConnor H. Beveridge
Connor H. Beveridge
PWPrageeth R. Wijewardhane
Prageeth R. Wijewardhane
GCGaurav Chopra
Gaurav Chopra
Statistical analysis and modeling of mass spectrometry (MS) data have a long and rich history with several modern MS-based applications using statistical and chemometric methods. Recently, machine learning (ML) has experienced a renaissance due to advents in computational hardware and the development of new algorithms for artificial neural networks (ANN) and deep learning architectures. Moreover, recent successes of new ANN and deep learning architectures in several areas of science, engineering, and society have further strengthened the ML field. Importantly, modern ML methods and architectures have enabled new approaches for tasks related to MS that are now widely adopted in several popular MS-based subdisciplines, such as mass spectrometry imaging and proteomics. Herein, we aim to provide an introductory summary of the practical aspects of ML methodology relevant to MS. Additionally, we seek to provide an up-to-date review of the most recent developments in ML integration with MS-based techniques while also providing critical insights into the future direction of the field.

6 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
PPPriya Prakash
Priya Prakash
PMPalak Manchanda
Palak Manchanda
EPEvangelia Paouri
Evangelia Paouri
KBKanchan Bisht
Kanchan Bisht
KSKaushik Sharma
Kaushik Sharma
GCGaurav Chopra
Gaurav Chopra
Summary: Several microglia-expressed genes have emerged as top risk variants for Alzheimer’s disease (AD). Impaired microglial phagocytosis is one of the main proposed outcomes by which these AD-risk genes may contribute to neurodegeneration, but the mechanisms translating genetic association to cellular dysfunction remain unknown. Here we show that microglia form lipid droplets (LDs) upon exposure to amyloid-beta (Aβ), and that their LD load increases with proximity to amyloid plaques in brains from human patients and the AD mouse model 5xFAD. LD formation is dependent on age and disease progression and is prominent in the hippocampus in mice and humans. Despite differences in microglial LD load between brain regions and sexes in mice, LD-laden microglia exhibited a deficit in Aβ phagocytosis. Unbiased lipidomic analysis identified a decrease in free fatty acids (FFAs) and a parallel increase in triacylglycerols (TGs) as the key metabolic transition underlying LD formation. DGAT2, a key enzyme for converting FFAs to TGs, promotes microglial LD formation and is increased in 5xFAD and human AD brains. Inhibition or degradation of DGAT2 improved microglial uptake of Aβ and drastically reduced plaque load in 5xFAD mice, respectively. These findings identify a new lipid-mediated mechanism underlying microglial dysfunction that could become a novel therapeutic target for AD.

15 October 2025 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
PWPrageeth R. Wijewardhane
Prageeth R. Wijewardhane
KSKatelyn Smith
Katelyn Smith
JFJonathan Fine
Jonathan Fine
JBJameson R. Bothe
Jameson R. Bothe
PWPeter Wuelfing
Peter Wuelfing
GCGaurav Chopra
Gaurav Chopra

25 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PWPrageeth R. Wijewardhane
Prageeth R. Wijewardhane
AWAdrienne Wells
Adrienne Wells
MMMatthew Muhoberac
Matthew Muhoberac
KLKai P. Leung
Kai P. Leung
GCGaurav Chopra
Gaurav Chopra
Scar formation is a process that occurs due to increased collagen deposition and uncontrolled inflammation. Previous studies have demonstrated that Pirfenidone (Pf), an FDA approved anti-inflammatory and anti-fibrotic drug can reduce inflammation in vivo as well as regulate activation of LPS-stimulated neutrophils. However, the molecular level mechanism of Pf’s action is not well understood. Here, we used neural networks to identify new targets and molecular modeling methods to investigate the Pf’s action pathways at the molecular level that are related to its ability to reduce both the inflammatory and remodeling phases of the wound healing process. Out of all the potential targets identified, both molecular docking and molecular dynamics results suggest that Pf has a noteworthy binding preference towards the active conformation of the p38 mitogen activated protein kinase-14 (MAPK14) and it is potentially a type I inhibitor-like molecule. In addition to p38 MAPK (MAPK14), additional potential targets of Pf include AKT1, MAP3K4, MAP2K3, MAP2K6, MSK2, MAP2K2, ERK1, ERK2, and PDK1. We conclude that several proteins/kinases, rather than a single target, are involved in Pf’s wound healing ability to regulate signaling, inflammation, and proliferation.

18 October 2026 in Analytical Chemistry
Verified
Journal Article
Closed access
CBConnor Beveridge
Connor Beveridge
PWPrageeth R. Wijewardhane
Prageeth R. Wijewardhane
MMMatthew Muhoberac
Matthew Muhoberac
NMNicolás M. Morato
Nicolás M. Morato
AKAndreas Kaerner
Andreas Kaerner
GCGaurav Chopra
Gaurav Chopra